Effects of Telmisartan on Ischemic Cardiovascular Events in High-risk Hypertensive Patients
NCT ID: NCT00863980
Last Updated: 2015-09-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
1500 participants
INTERVENTIONAL
2009-04-30
2013-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of the Effect of Telmisartan (Micardis® 80 mg/ MicardisPlus® 80/12.5 mg) on Blood Pressure and Cardiovascular Risk Factor Index in High Risk Hypertensive Patients
NCT00904371
Effectiveness of MICARDIS® (Telmisartan) on Blood Pressure Control and Quality of Live in Patients With Essential Hypertension
NCT02242370
J-TARGET,Japanese Telmisartan Study for Antihypertensive Good Effect in Long Term Observation
NCT00659581
Filtered Trial for Telmisartan 40mg Non-responder
NCT00550953
Investigating the Effect of Telmisartan (Micardis®) on the Average 24h Blood Pressure of Therapy-naive and Therapy-experienced Patients
NCT00879411
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Study design: PROBE(Prospective, Randomized, Open-labeled Blind Endpoints)
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Telmisartan
Treatment with Telmisartan
Micardis (Telmisartan)
40-80 mg/day oral administration
Candesartan
Treatment with Candesartan
Blopress (Candesartan)
8-12 mg/day oral administration
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Micardis (Telmisartan)
40-80 mg/day oral administration
Blopress (Candesartan)
8-12 mg/day oral administration
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Myocardial infarction at least 12 months before enrollment and not planned for percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG)
* Angina pectoris or asymptomatic myocardial ischemia undergoing percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) at least 12 months before enrollment and not planned for further percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG)
2. Peripheral arterial disease undergoing percutaneous transluminal angioplasty (PTA) or peripheral artery bypass grafting at least 6 months before enrollment
3. Symptomatic cerebral infarction or cerebral hemorrhage at least 6 months before enrollment
Exclusion Criteria
2. Planned elective percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) within the anteceding 3 months
3. History of myocardial infarction, unstable angina pectoris, percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) within the preceding 12 months
4. History of percutaneous hind limb angioplasty (PTA) or bypass grafting within the preceding 6 months
5. History of cerebral infarction, cerebral hemorrhage within the past 6 months
6. Congenital heart disease
7. Uncontrolled hypertension on treatment (eg, BP\>180/110 mmHg)
8. Pregnant women or women of childbearing potential
9. Hepatic dysfunction (AST or ALT \>100IU/L)
10. Renal impairment (serum creatinine level \>2.0 mg per 100 ml)
11. Known hypersensitivity or intolerance to ARB
30 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kyoto Prefectural University of Medicine
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hiroyuki Yamada
Department of Cardiovascular Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hiroaki Matsubara, MD, PhD
Role: STUDY_CHAIR
Kyoto Prefectural University of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shakaihoken Kobe Central Hospital
Kobe, Kobe, Japan
Akashi Municipal Hospital
Kobe, Kobe, Japan
Kouseikai Takeda Hospital
Kyoto, Kyoto, Japan
Aijyukai Dohjin Hospital
Kyoto, Kyoto, Japan
Kyoto Second Red Cross Hospital
Kyoto, Kyoto, Japan
Kyoto Prefectural University of Medicine
Kyoto, Kyoto, Japan
Social Insurance Kyoto Hospital
Kyoto, Kyoto, Japan
Kyoto Kojyo Hokenkai
Kyoto, Kyoto, Japan
Kyoto City Hospital
Kyoto, Kyoto, Japan
Kyoto First Red Cross Hospital
Kyoto, Kyoto, Japan
Aiseikai Yamashina Hospital
Kyoto, Kyoto, Japan
Tanabe Central Hospital
Kyoto, Kyoto, Japan
Rakusai Simizu Hospital
Kyoto, Kyoto, Japan
Uji Hospital
Kyoto, Kyoto, Japan
Kyoto Yawata Hospital
Kyoto, Kyoto, Japan
Seizinkai Simizu Hospital
Kyoto, Kyoto, Japan
Saiseikai Kyoto Hospital
Kyoto, Kyoto, Japan
Public Yamasiro Hospital
Kyoto, Kyoto, Japan
Gakkentoshi Hospital
Kyoto, Kyoto, Japan
Fukuchiyama City Hospital
Kyoto, Kyoto, Japan
Ayabe City Hospital
Kyoto, Kyoto, Japan
Maizuru Red Cross Hospital
Kyoto, Kyoto, Japan
National Hospital Organization Maizuru Medical Center
Kyoto, Kyoto, Japan
Maizuru Kyosai Hospital
Kyoto, Kyoto, Japan
Public Nantan Hospital
Kyoto, Kyoto, Japan
Kyoto Prefectural Yosanoumi Hospital
Kyoto, Kyoto, Japan
Kumihama Hospital
Kyoto, Kyoto, Japan
Sakurakai Takahashi Hospital
Kyoto, Kyoto, Japan
Yuuseikai Midorigaoka Hospital
Osaka, Osaka, Japan
Matsushita Memorial Hospital
Osaka, Osaka, Japan
Saiseikai Shiga Hospital
Shiga, Shiga, Japan
Omihachiman Community Medical Center
Shiga, Shiga, Japan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UMIN000001762
Identifier Type: -
Identifier Source: secondary_id
C-486
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.